140 related articles for article (PubMed ID: 21858815)
1. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients.
Tachezy M; Effenberger K; Zander H; Minner S; Gebauer F; Vashist YK; Sauter G; Pantel K; Izbicki JR; Bockhorn M
Int J Cancer; 2012 Jul; 131(2):396-405. PubMed ID: 21858815
[TBL] [Abstract][Full Text] [Related]
2. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
4. Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Taniguchi T; Yokoi K; Osada H; Sekido Y
J Surg Res; 2013 Jan; 179(1):24-32. PubMed ID: 22985775
[TBL] [Abstract][Full Text] [Related]
5. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
6. Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?
Erturk K; Tastekin D; Bilgin E; Serilmez M; Bozbey HU; Sakar B
Biomed Pharmacother; 2016 Feb; 77():86-91. PubMed ID: 26796270
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of activated leukocute cell adhesion molecule in gastric cancer is associated with advanced stages and poor prognosis and miR-9 deregulation.
Ye M; Du YL; Nie YQ; Zhou ZW; Cao J; Li YF
Mol Med Rep; 2015 Mar; 11(3):2004-12. PubMed ID: 25395097
[TBL] [Abstract][Full Text] [Related]
8. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.
King JA; Ofori-Acquah SF; Stevens T; Al-Mehdi AB; Fodstad O; Jiang WG
Breast Cancer Res; 2004; 6(5):R478-87. PubMed ID: 15318930
[TBL] [Abstract][Full Text] [Related]
9. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
10. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma.
Verma A; Shukla NK; Deo SV; Gupta SD; Ralhan R
Oncology; 2005; 68(4-6):462-70. PubMed ID: 16024937
[TBL] [Abstract][Full Text] [Related]
11. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
Burkhardt M; Mayordomo E; Winzer KJ; Fritzsche F; Gansukh T; Pahl S; Weichert W; Denkert C; Guski H; Dietel M; Kristiansen G
J Clin Pathol; 2006 Apr; 59(4):403-9. PubMed ID: 16484444
[TBL] [Abstract][Full Text] [Related]
13. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer.
Vashist YK; Effenberger KE; Vettorazzi E; Riethdorf S; Yekebas EF; Izbicki JR; Pantel K
Ann Surg; 2012 Jun; 255(6):1105-12. PubMed ID: 22580852
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.
Ribeiro KB; da Silva Zanetti J; Ribeiro-Silva A; Rapatoni L; de Oliveira HF; da Cunha Tirapelli DP; Garcia SB; Feres O; da Rocha JJ; Peria FM
Cancer Biomark; 2016 Mar; 16(4):513-21. PubMed ID: 27062566
[TBL] [Abstract][Full Text] [Related]
15. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Wachowiak R; Mayer S; Kaifi J; Gebauer F; Izbicki JR; Lacher M; Bockhorn M; Tachezy M
Anticancer Res; 2016 Aug; 36(8):3991-5. PubMed ID: 27466504
[TBL] [Abstract][Full Text] [Related]
17. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer.
Hong X; Michalski CW; Kong B; Zhang W; Raggi MC; Sauliunaite D; De Oliveira T; Friess H; Kleeff J
J Surg Oncol; 2010 Jun; 101(7):564-9. PubMed ID: 20461761
[TBL] [Abstract][Full Text] [Related]
18. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy.
Jezierska A; Matysiak W; Motyl T
Med Sci Monit; 2006 Aug; 12(8):BR263-73. PubMed ID: 16865058
[TBL] [Abstract][Full Text] [Related]
19. Activated leukocyte cell adhesion molecule is a marker for thyroid carcinoma aggressiveness and disease-free survival.
Chaker S; Kak I; MacMillan C; Ralhan R; Walfish PG
Thyroid; 2013 Feb; 23(2):201-8. PubMed ID: 23148625
[TBL] [Abstract][Full Text] [Related]
20. Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
Ishiguro F; Murakami H; Mizuno T; Fujii M; Kondo Y; Usami N; Yokoi K; Osada H; Sekido Y
J Thorac Oncol; 2012 May; 7(5):890-9. PubMed ID: 22722789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
